[1] PULLIRSCH D, JANTSCH M F. Proteome diversification by adenosine to inosine RNA editing[J].RNA Biol, 2010, 7(2):205-212. [2] LIDDICOAT B J, PISKOL R, CHALK A M, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself[J]. Science, 2015,349(6252):1115-1120. [3] HARTNER J C, WALKLEY C R, LU J, et al. ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling[J]. Nat Immunol, 2009,10(1):109-115. [4] MANNION N M, GREENWOOD S M, YOUNG R, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA[J]. Cell Rep, 2014,9(4):1482-1494. [5] KIM Y K, FURIC L, DESGROSEILLERS L, et al. Mammalian Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay[J]. Cell, 2005,120(2):195-208. [6] PARK E, GLEGHORN M L, MAQUAT L E. Staufen2 functions in Staufen1-mediated mRNA decay by binding to itself and its paralog and promoting UPF1 helicase but not ATPase activity[J]. Proc Natl Acad Sci U S A, 2013, 110(2):405-412. [7] SHOSHAN E, MOBLEY A K, BRAEUER R R, et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis[J]. Nat Cell Biol, 2015,17(3):311-321. [8] QIN Y R, QIAO J J, CHAN T H, et al. Adenosine-to-inosine RNA editing mediated by ADARs in esophageal squamous cell carcinoma[J]. Cancer Res, 2014,74(3):840-851. [9] JIANG Q, CREWS L A, BARRETT C L, et al. ADAR1 promotes malignant progenitor reprogramming in chronic myeloid leukemia[J]. Proc Natl Acad Sci USA, 2013,110(3):1041-1046. [10] CHEN Y, WANG H, LIN W Y, et al. ADAR1 overexpression is associated with cervical cancer progression and angiogenesis[J]. Diagn Pathol, 2017, 12(1):12. [11] AMIN E M, LIU Y, DENG S, et al. The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing FAK[J]. Sci Signal, 2017,10(497):eaah3941. [12] BASS B L. RNA editing by adenosine deaminases that act on RNA[J]. Annu Rev Biochem, 2002,71:817-846. [13] HEEP M, MACH P, REAUTSCHNIG P, et al. Applying human ADAR1p110 and ADAR1p150 for site-directed RNA editing-G/C substitution stabilizes GuideRNAs against editing[J]. Genes (Basel), 2017, 8(1):E34. [14] LIU Y, LEI M, SAMUEL C E. Chimeric double-stranded RNA-specific adenosine deaminase ADAR1 proteins reveal functional selectivity of double-stranded RNA-binding domains from ADAR1 and protein kinase PKR[J]. Proc Natl Acad Sci U S A, 2000,97(23):12541-12546. [15] QUINONES-VALDEZ G, TRAN S S, JUN H I, et al. Regulation of RNA editing by RNA-binding proteins in human cells[J]. Commun Biol, 2019,2:19. [16] NIE Y, DING L, KAO P N, et al. ADAR1 interacts with NF90 through double-stranded RNA and regulates NF90-mediated gene expression independently of RNA editing[J]. Mol Cell Biol, 2005,25(16):6956-6963. [17] AGRANAT L, RAITSKIN O, SPERLING J, et al. The editing enzyme ADAR1 and the mRNA surveillance protein hUpf1 interact in the cell nucleus[J]. Proc Natl Acad Sci U S A, 2008,105(13):5028-5033. [18] OTA H, SAKURAI M, GUPTA R, et al. ADAR1 forms a complex with Dicer to promote microRNA processing and RNA-induced gene silencing[J]. Cell, 2013,153(3):575-589. [19] CHEN L, LI Y, LIN C H, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma[J]. Nat Med, 2013,19(2):209-216. [20] HAN S W, KIM H P, SHIN J Y, et al. RNA editing in RHOQ promotes invasion potential in colorectal cancer[J]. J Exp Med, 2014,211(4):613-621. [21] DOU N, YU S, YE X, et al. Aberrant overexpression of ADAR1 promotes gastric cancer progression by activating mTOR/p70S6K signaling[J]. Oncotarget, 2016,7(52):86161-86173. [22] ANADÓN C, GUIL S, SIMÓ-RIUDALBAS L, et al. Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis[J]. Oncogene, 2016, 35(33):4422. [23] SUN Y, FAN J, WANG B, et al. The aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer by stabilizing c-Myc[J]. Am J Cancer Res, 2020,10(1):148-163. [24] CHEN T, YOU Y N, JIANG H, et al. Epithelial-mesenchymal transition (EMT):a biological process in the development, stem cell differentiation, and tumorigenesis[J]. J Cell Physiol, 2017, 232(12):3261-3272. [25] MA P, NI K, KE J, et al. miR-448 inhibits the epithelial-mesenchymal transition in breast cancer cells by directly targeting the E-cadherin repressor ZEB1/2[J]. Exp Biol Med (Maywood), 2018,243(5):473-480. [26] PARK J J, PARK M H, OH E H, et al. The p21-activated kinase 4-Slug transcription factor axis promotes epithelial-mesenchymal transition and worsens prognosis in prostate cancer[J]. Oncogene, 2018,37(38):5147-5159. |